Thermo Fisher Scientific Exhibits New Solutions and Expanded Capabilities at CPHI Milan

Thermo Fisher Scientific announced it is showcasing new and expanded services at CPHI Milan, which is happening from October 6-8, 2026. The company will be presenting new drug development solutions, expanded capacity, and digital technologies.¹

New offerings from the company include its OSD Express, which is designed to increase predictability and advance oral solid dosage (OSD) drug development, according to the company, and is part of a its Accelerator Drug Development approach to connect scientific expertise and capabilities across drug development, clinical trials, endpoint solutions, clinical supply, and laboratory services to reduce handoffs and maintain continuity as programs advance.

The company is expanding its small-molecule capabilities through a collaboration with AustinPx that gives its customers access to the KinetiSol solvent-free technology. This technology is designed to improve bioavailability of poorly soluble drugs.

Therm Fisher Scientific’s expanded services include investments in tableting, laboratory, and packaging capabilities. It is also expanding its OSD development and commercial manufacturing with new dry granulation technology and improved tablet manufacturing in it Bourgoin, France, and Whitby, Canada facilities. Serialized packaging capabilities have also been expanded in the company’s Cincinnati and Toronto facilities.

What’s New in Sterile Manufacturing

The company’s Steriles Express Solutions provide a defined approach to early development and late-stage technology transfer. It can provide phase 1 or phase 2 clinical material in 20 weeks. Its Steriles Express Tech Transfer can provide a phase 3 good manufacturing practice (GMP) batch in as as few as 26 weeks; although, the company notes timelines may vary based on defined program parameters and scope.

Investments in sterile drug product capacity include new and expanded lines for development and commercial manufacturing of vials and prefilled syringes at the company’s Plainville, Massachusetts; Monza, Italy; and Ferentino, Italy, facilities. Fill-finish and drug-device capabilities are also being expanded at the company’s Ridgefield, New Jersey facility.

“Drug development increasingly depends on decisions and capabilities that span traditional boundaries, from development and manufacturing to clinical supply and clinical execution,” said Mike Shafer, executive vice president and president, Biopharma Services, Thermo Fisher Scientific, in a press release.¹ “We’re investing not only in capacity, but in how those capabilities connect. That gives our customers greater continuity as they navigate critical transitions, scale their programs, and prepare for commercialization.”

Capabilities Across the Development Pathway

Thermo Fisher Scientific is also investing in new bioprocessing equipment at ists Plainville facility, which will expand its current GMP (CGMP) monoclonal antibody manufacturing capacity in the United States. And the company’s U.S. Bioprocess Design Center helps customers translate process innovations into scalable solutions for biologics development and manufacturing. Its Gibco cell culture media portfolio has also been expanded with CHO-K1 Catalog Panel Media and Feed, a CGMP-ready portfolio designed to support cell growth and protein production.

A 52,000-square-foot expansion in Bohemia, New York, will increase clinical label manufacturing capacity, and a new facility in Heiwajima, Tokyo, is expected to approximately double Japan’s storage, distribution, and secondary packaging capacity, ranging from controlled ambient to ultra-low temperature. The company is also planning investments in technologies to support drug-device combination product assembly, labeling and packaging.

Digital Technologies

Generative artificial intelligence (AI) is being used to accelerate clinical development in the company’s PPD clinical research business, with a 50% aggregate reduction in master informed consent form draft time.

The company is also expanding evidence-generation capabilities through the PPD CorEvitas Vitiligo Registry, which generates longitudinal real-world evidence on treatment effectiveness, disease burden, and patient outcomes.

Panel Presentations at CPHI Milan

Thermo Fisher experts will be presenting discussion panels at CPHI Milan, including the following:

• CDMO Consolidation: Strategic Partnerships or Dangerous Dependencies?—Hannah Spaepen, senior director, CMC Portfolio Management, Pharma Services, will participate as a panelist Tuesday, Octobert 6, from 11:35 a.m. – 12:20 p.m. CET.
• Putting AI to work in drug development: Practical applications that deliver measurable value—Anil Kane, global head of Technical and Scientific Affairs, Pharma Services, will present Wednesday, Oct. 7, from 1:45 – 2:10 p.m. CET.

Thermo Fisher Scientific will be located at booth 6A2 during the event. For more CPHI Milan coverage, visit PharmTech’s conference page.

Reference

1. Thermo Fisher Scientific showcases new solutions and expanded capabilities to accelerate drug development at CPHI Milan 2026. Press release. Thermo Fisher Scientific. October 6, 2026.